Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
Two main objectives are: Accelerate novel technologies and products for global markets; and Connect academia and industry, creating synergy for faster advancement of the Bioprotection sector
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Collaboration supports multiple discovery efforts, including vaccines
Company appoints five new independent directors to reconstituted board
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
Advancing to IND-enabling studies with multiple drug candidates
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
The new program includes upstream and downstream process development and large-scale GMP production.
SPLASH also houses the tools’ calibration for epMotion, Eppendorf automated liquid handling workstations.
We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
Bayer now present in four of the largest biotechnology hubs in the United States
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
